Enovis Reports Mixed Q2 2026 Results with Reconstructive Growth
Event summary
- Q2 2026 sales grew 3% reported, 5% organic to $583M.
- Reconstructive segment up 8% reported, 6% organic; P&R down (1%) reported, up 3% organic.
- Adjusted EBITDA at $104M (17.9% margin), net loss of $1M.
- Full-year guidance reaffirmed: revenue $2.31-2.37B (4-6% organic growth).
- CEO Damien McDonald highlights progress but notes macroeconomic challenges ahead.
The big picture
Enovis' Q2 results reflect a reshaped portfolio with Reconstructive leading growth, but P&R challenges persist. The company's ability to navigate macroeconomic volatility and sustain operational agility will be critical as it targets 4-6% organic revenue growth for 2026. Integration of the Lima acquisition remains a strategic focus amid broader healthcare technology trends favoring clinically differentiated solutions.
What we're watching
- Segment Momentum
- Whether Reconstructive's 8% growth can offset P&R declines amid macroeconomic headwinds.
- Execution Risk
- The pace at which Enovis integrates Lima and sustains innovation pipeline momentum.
- Macro Sensitivity
- How dynamic end markets impact full-year guidance amid inflationary pressures.